Tirzepatide in Tay Ho: How Trial Endpoints, Treatment Duration, and Participant Profiles Affect Results

Key Takeaways

• Endpoints define the research question. HbA1c, percentage body-weight change, cardiovascular events, and safety outcomes measure different dimensions of treatment effect.
• Study duration changes what can be observed. A 40-week diabetes trial and a 72-week obesity trial differ in both their duration and their primary scientific purpose.
• Participant profiles determine applicability. Diabetes status, baseline HbA1c, body mass index (BMI), previous treatment, and other characteristics affect how directly a result applies to another population.
• Comparators matter. Tirzepatide versus placebo and tirzepatide versus an active medicine answer different questions.
• Statistical estimands matter too. Results that include outcomes after treatment discontinuation can differ from estimates of what might happen if participants remained on treatment as intended.
• Mean results are not individual predictions. Group averages do not guarantee that every participant will experience the same magnitude of change.
• Safety and efficacy require separate interpretation. A trial can demonstrate a favorable average outcome while still identifying adverse events, discontinuations, or limitations in generalizability.

1. Why Clinical Trial Results Need Context

Clinical research does not produce a single number that fully describes a medicine. Instead, a trial is designed to answer a defined question under specified conditions. The protocol determines who can participate, what treatment is compared, how outcomes are measured, and when those outcomes are assessed.

Tirzepatide illustrates why these details matter. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its clinical research program has investigated glycemic control in type 2 diabetes, weight management in people with obesity or overweight, and other outcomes in defined populations.

These research questions overlap biologically but are not identical. Improved glycemic control may be reflected in HbA1c, whereas weight-management efficacy is commonly described using percentage change in body weight and the proportion of participants reaching prespecified weight-loss thresholds. Cardiovascular safety trials may focus on major cardiovascular events rather than either of those outcomes.

The correct interpretation therefore starts with the question the investigators intended to answer, not the headline number reported in the abstract.

2. What Is a Clinical Trial Endpoint?

An endpoint is an outcome used to evaluate a treatment’s effects. The primary endpoint is the main outcome specified for the trial’s principal analysis. Key secondary endpoints address additional prespecified questions, while exploratory endpoints may generate hypotheses for future research.

Choosing an endpoint affects how treatment success is defined. It also influences sample-size calculations, statistical testing, follow-up schedules, and how results should be communicated.

2.1 HbA1c as an endpoint

Glycated hemoglobin, or HbA1c, reflects average blood glucose over approximately the preceding two to three months, with the precise relationship influenced by red-cell biology and other factors. Trials in type 2 diabetes commonly assess change in HbA1c from baseline to a specified time point.

A reduction in HbA1c is evidence of improved glycemic control in the population studied. It is not, by itself, proof of a specific magnitude of weight loss, a reduction in cardiovascular events, or long-term prevention of diabetes complications. Those questions require suitable outcomes and study designs.

2.2 Percentage change in body weight

Weight-management trials often use percentage change from baseline because it accounts for differences in starting body weight. A change of 10 kg, for example, represents a different proportion of baseline weight for someone starting at 80 kg than for someone starting at 120 kg.

Trials may also evaluate categorical endpoints such as the proportion of participants achieving at least 5%, 10%, 15%, or 20% weight reduction. These thresholds communicate how many participants reached a specified level of change, complementing the average change across the group.

However, the percentage of participants crossing a threshold is not equivalent to the average percentage change. Both can be useful, but they describe different aspects of the results.

2.3 Safety endpoints and tolerability

Safety outcomes include adverse events, serious adverse events, treatment discontinuations, and clinically relevant laboratory or physiological changes. Their interpretation depends on the definitions used, the period during which events are collected, and how thoroughly participants are followed.

For example, a gastrointestinal event reported during dose escalation may have a different time pattern from an event identified after prolonged treatment. A study’s overall adverse-event rate does not necessarily describe the severity, timing, or clinical significance of every event.

3. SURPASS and SURMOUNT: Different Questions, Different Endpoints

The SURPASS program primarily investigated tirzepatide in adults with type 2 diabetes. SURMOUNT-1 evaluated tirzepatide for weight management in adults with obesity or overweight and a weight-related complication who did not have diabetes.

Sources: SURPASS-2, New England Journal of Medicine; SURMOUNT-1, New England Journal of Medicine.

These studies should not be treated as direct head-to-head evidence against each other. Their participant populations, comparators, primary endpoints, and assessment times differ. A cross-trial comparison can help describe the research landscape, but it cannot replace a randomized comparison designed to answer a specific comparative question.

4. What SURPASS-2 Tells Us About Glycemic Endpoints

SURPASS-2 was an open-label, randomized phase 3 trial comparing tirzepatide at 5 mg, 10 mg, or 15 mg once weekly with semaglutide 1 mg once weekly in adults with type 2 diabetes receiving metformin. The primary endpoint was the change in HbA1c from baseline to week 40.

The trial enrolled 1,879 participants. Mean baseline HbA1c was approximately 8.28%, mean age was 56.6 years, and mean body weight was 93.7 kg. At week 40, estimated mean HbA1c changes were −2.01, −2.24, and −2.30 percentage points for the three tirzepatide groups, respectively, compared with −1.86 percentage points for semaglutide.

The study found that tirzepatide was noninferior and statistically superior to semaglutide 1 mg for the primary endpoint under the trial’s prespecified analysis. Weight change was a key secondary endpoint, and the reported mean weight reductions were greater in the tirzepatide groups than in the comparator group.

The endpoint hierarchy matters. The primary conclusion was about HbA1c at week 40, not about every possible metabolic outcome or long-term complication. Secondary outcomes add information, but their interpretation depends on the statistical testing plan and whether the study was designed and powered to evaluate them.

5. What SURMOUNT-1 Tells Us About Weight Endpoints

SURMOUNT-1 was a phase 3, double-blind, randomized, placebo-controlled trial involving 2,539 adults with a BMI of at least 30, or at least 27 with a weight-related complication, excluding diabetes. Participants were assigned to tirzepatide 5 mg, 10 mg, or 15 mg once weekly, or placebo, for 72 weeks. The trial included a 20-week dose-escalation period.

The coprimary endpoints were percentage change in body weight from baseline and the proportion of participants achieving at least 5% weight reduction at week 72. Mean baseline body weight was 104.8 kg, mean BMI was 38.0, and 94.5% of participants had a BMI of at least 30.

Using the treatment-regimen estimand, mean body-weight change at week 72 was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg tirzepatide, compared with −3.1% with placebo. The proportion achieving at least 5% weight reduction was 85.1%, 88.9%, and 90.9%, respectively, versus 34.5% with placebo.

These figures demonstrate the effects observed in this trial under its specified design and analysis. They should not be interpreted as guaranteed outcomes for an individual or as estimates that automatically apply to people with type 2 diabetes, people outside the study’s BMI criteria, or people receiving different treatment regimens.

The trial also assessed secondary outcomes such as waist circumference, cardiometabolic measures, physical function, and selected body-composition measures. Each endpoint answers a different question. For example, waist circumference can provide information about abdominal size, but it is not a direct measurement of visceral fat mass.

6. Why Treatment Duration Changes the Interpretation

Duration determines how much time participants have to experience the treatment, reach a stable treatment phase, and contribute data to the study’s endpoint assessment. It also affects which safety patterns can be observed.

6.1 Early response versus later response

Early measurements can capture the initial response to treatment, including changes during dose escalation. Later measurements may reflect a longer period of exposure and additional changes in body weight or glycemic control. These phases are not necessarily interchangeable.

In SURMOUNT-1, the 72-week endpoint followed a 20-week dose-escalation period. The final result therefore reflects an extended treatment period, not 72 weeks spent entirely at the assigned maintenance dose. A reader who overlooks dose escalation may misunderstand the time course represented by the headline result.

6.2 Forty weeks and 72 weeks are not equivalent windows

SURPASS-2 assessed its primary glycemic endpoint at week 40, whereas SURMOUNT-1 assessed its coprimary weight endpoints at week 72. The longer follow-up in SURMOUNT-1 provides more time to observe weight trajectories under that study’s regimen. It does not, by itself, establish that the treatment is more effective than in SURPASS-2 because the studies measured different outcomes in different populations.

6.3 Long-term outcomes require longer observation

Some questions, including durability of weight change, progression to diabetes, or the incidence of relatively uncommon adverse outcomes, may require longer follow-up than a conventional efficacy trial. Extended follow-up can add important information, but interpretation should account for retention, adherence, changes in treatment, and whether the extension preserves the original randomized comparison.

For example, a three-year analysis of participants with obesity and prediabetes from the SURMOUNT-1 program examined tirzepatide treatment over 176 weeks followed by a 17-week off-treatment period. This is a different time horizon and research question from the original 72-week primary analysis. Long-term findings should be cited from the specific report rather than inferred from the original publication.

7. Participant Profiles: Who Was Actually Studied?

Participant characteristics define the population to which trial results most directly apply. Important factors include age, sex, baseline BMI, diabetes status, HbA1c, duration of diabetes, prior medicines, and the presence of other medical conditions.

7.1 Diabetes status

SURPASS-2 enrolled adults with type 2 diabetes, while SURMOUNT-1 excluded diabetes. This distinction matters because glucose regulation, baseline HbA1c, concomitant treatment, and the relevance of glycemic endpoints differ between these populations.

Weight changes observed in an obesity trial without diabetes should not automatically be treated as the expected result in a diabetes population. Conversely, HbA1c reductions observed in a diabetes trial do not directly quantify the effects of treatment in people without diabetes.

7.2 Baseline BMI and starting weight

Baseline BMI and body weight influence how weight change is expressed and how directly a participant resembles the trial population. A trial enrolling mostly adults with obesity may not fully represent people with lower BMI or a different distribution of weight-related complications.

Percentage change makes results easier to compare across starting weights, but it does not remove all differences between populations. Baseline health, body composition, concomitant treatment, and study eligibility criteria can still affect interpretation.

7.3 Baseline disease severity and previous treatment

Baseline HbA1c and diabetes duration can influence the scope for observed glycemic improvement. Existing medicines can also affect glucose and weight outcomes. For example, SURPASS-2 evaluated tirzepatide as an addition to metformin, so its results should be interpreted in that treatment context.

Participants in other trials may have different levels of disease severity, treatment history, or cardiovascular risk. These differences are not necessarily flaws; they reflect different research questions. They do mean that results should not be generalized without considering how closely another population matches the enrolled participants.

7.4 Eligibility criteria and generalizability

Randomized trials use inclusion and exclusion criteria to define a population and reduce avoidable risk. Those criteria support internal validity but can limit generalizability to people who were underrepresented or excluded.

Generalizability is therefore a question of degree: how similar is the population of interest to the trial population in characteristics that could affect treatment response or safety? A statistically robust trial can still leave uncertainty about populations that were not adequately represented.

8. Comparator Choice and Statistical Estimands

8.1 Placebo-controlled versus active-comparator trials

A placebo-controlled trial estimates the treatment effect relative to placebo within the study design, often with both groups receiving background lifestyle or standard-care measures. An active-comparator trial evaluates a medicine relative to another treatment.

These designs answer different questions. SURMOUNT-1 compared tirzepatide with placebo, whereas SURPASS-2 compared tirzepatide with semaglutide 1 mg. A difference observed in one design should not be compared directly with a difference from another design without accounting for the comparator, baseline characteristics, endpoint, and follow-up period.

8.2 What is an estimand?

An estimand is a precise definition of the treatment effect a trial aims to estimate, including how events that occur after randomization—such as treatment discontinuation or use of rescue medication—are handled.

In SURMOUNT-1, the treatment-regimen estimand assessed the treatment effect regardless of treatment discontinuation in the intention-to-treat population. The efficacy estimand addressed the effect under a hypothetical scenario in which treatment was administered as intended. These approaches answer different questions and can yield different estimates.

The treatment-regimen estimand is useful for understanding outcomes under a treatment strategy that includes discontinuations as they occurred in the trial. The efficacy estimand can help describe the effect under continued intended treatment, but it depends on statistical assumptions used to estimate that hypothetical scenario.

8.3 Missing data and treatment discontinuation

Missing outcome data can affect trial estimates, especially when participants discontinue because of adverse effects, lack of efficacy, or other reasons associated with the outcome. Investigators use prespecified statistical methods to handle missing data, and the assumptions behind those methods matter.

When comparing results, check which analysis population and estimand are reported. A result based on a treatment-regimen estimand should not be casually compared with a result based on an efficacy estimand as though the two measure exactly the same quantity.

9. Statistics: A Practical Comparison of Key Trial Results

Sources: SURPASS-2; SURMOUNT-1; SURPASS-4.

How to read this table: These are not four directly comparable measures of the same effect. The results use different endpoints, follow-up periods, populations, and comparators. The table is intended to show why trial context matters—not to rank the studies by the size of their numerical changes.

10. Common Mistakes When Interpreting Tirzepatide Studies

• Comparing unlike endpoints: HbA1c reduction and percentage weight change measure different outcomes and use different units.
• Ignoring baseline characteristics: Starting BMI, HbA1c, diabetes status, and previous treatment affect the interpretation of results.
• Treating follow-up duration as a quality ranking: Longer follow-up can answer additional questions, but it does not automatically make a trial more relevant to every research question.
• Confusing statistical significance with clinical meaning: A low P value does not independently establish the magnitude, importance, or applicability of an outcome.
• Ignoring confidence intervals: An estimate has uncertainty. Confidence intervals help show the precision of a result and should be considered alongside the point estimate.
• Overgeneralizing from subgroup analyses: Subgroups can be informative, but smaller samples and multiple comparisons can limit the strength of conclusions.
• Confusing an efficacy estimate with an individual forecast: A group average cannot predict exactly what will happen to a particular person.
• Equating efficacy with overall benefit-risk: Safety, tolerability, discontinuation, and regulatory context must be assessed alongside efficacy endpoints.

11. Safety, Regulatory Status, and Research Limitations

Tirzepatide is a prescription medicine in jurisdictions where approved. Product indications and labeling differ across markets. Readers in Vietnam should verify current local regulatory status and use official product information rather than assuming that approval in another country establishes local authorization.

Clinical trials have reported gastrointestinal adverse events including nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Safety interpretation should consider the severity and timing of events, the number of participants affected, discontinuation rates, and the duration of follow-up. The current official prescribing information should be consulted for contraindications, warnings, and precautions relevant to each approved product.

Trial results also have limits. Randomized controlled trials provide strong evidence for outcomes measured under their protocols, but no single trial answers every question about longer-term use, all patient populations, rare adverse outcomes, or real-world treatment patterns. Post-marketing surveillance, additional trials, and longer-term follow-up may add evidence over time.

Research-grade products are not interchangeable with approved prescription medicines. A product listing does not establish clinical efficacy, pharmaceutical quality, regulatory authorization, or suitability for human use.

12. Related Research Products and Educational Resources

Related Articles and Resources

• Vietnam Peptides Knowledge Hub — browse educational articles about peptide science and clinical research.
• Peptide Research FAQ — review general terminology and research-product questions.
• Peptide Products Overview — explore product categories while distinguishing research listings from approved medicines.

13. Frequently Asked Questions

1. What is the most important endpoint in a tirzepatide trial?

There is no single endpoint that is most important for every trial. The primary endpoint is the main outcome specified for the study’s principal analysis. In SURPASS-2 it was HbA1c change at week 40; in SURMOUNT-1 the coprimary endpoints were percentage change in body weight and at least 5% weight reduction at week 72.

2. Why did SURPASS-2 and SURMOUNT-1 use different endpoints?

They addressed different research questions and enrolled different populations. SURPASS-2 investigated glycemic control in adults with type 2 diabetes, whereas SURMOUNT-1 evaluated weight management in adults with obesity or overweight who did not have diabetes.

3. Does a longer trial always provide better evidence?

Not automatically. Longer follow-up can reveal the durability of effects and additional safety information, but the value of a trial depends on whether its design and endpoints answer the question being asked. A shorter, well-designed trial may be highly informative for a defined endpoint.

4. Why do baseline HbA1c and BMI matter?

They describe important starting characteristics. Baseline HbA1c helps contextualize glycemic changes, while BMI and body weight help define the population and interpret weight outcomes. Results may differ in populations with substantially different starting characteristics.

5. What does a 20% mean weight reduction tell us?

It describes the average percentage change in the studied group when reported as a mean, or a threshold outcome if the result is the proportion reaching at least 20% reduction. Those are different statistics and should not be confused.

6. Why can two analyses of the same trial report different estimates?

Analyses may use different estimands, populations, or assumptions about treatment discontinuation, rescue medication, and missing data. The analysis method should be checked before interpreting apparent differences.

7. Can results from people with type 2 diabetes be applied directly to people without diabetes?

Not without qualification. The populations differ in disease status, baseline glycemia, concomitant treatment, and potentially other characteristics. Results from each trial should be interpreted within its inclusion criteria and study design.

8. What is the difference between a primary and a secondary endpoint?

The primary endpoint is the main outcome used to evaluate the trial’s principal hypothesis. Secondary endpoints assess additional prespecified questions. Secondary results can be important, but their statistical interpretation depends on the testing hierarchy and analysis plan.

9. Does statistical significance mean that everyone benefits?

No. Statistical significance describes evidence against a specified null hypothesis under the statistical model. It does not mean every participant experienced the same response, and it does not guarantee a clinically meaningful outcome for every individual.

10. How should I compare tirzepatide results across studies?

Start with the endpoint, baseline participant characteristics, comparator, duration, analysis population, estimand, and confidence intervals. If these differ materially, avoid treating the results as direct comparisons unless a suitable comparative analysis supports that conclusion.

14. Scientific References

1. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503–515. DOI: 10.1056/NEJMoa2107519. PubMed.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. DOI: 10.1056/NEJMoa2206038. PubMed.
3. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398:1811–1824. PubMed.
4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392:958–971. DOI: 10.1056/NEJMoa2410819. PubMed.
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. 2019. Official guideline PDF.
6. U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. Consult the current official labeling for product-specific indications, warnings, precautions, and clinical pharmacology. Official FDA label.
7. U.S. Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Although disease-specific, this FDA resource provides general context on endpoint selection and interpretation in drug development. FDA guidance page.

Conclusion

Tirzepatide trial results become much easier to interpret when endpoints, duration, and participant profiles are considered together. SURPASS-2 provides evidence about glycemic control in adults with type 2 diabetes over 40 weeks, while SURMOUNT-1 provides evidence about weight management over 72 weeks in adults with obesity or overweight without diabetes. Neither study should be used as a substitute for the other.

The most reliable way to compare clinical findings is to identify the exact outcome measured, determine who was enrolled, understand the comparator and follow-up period, and check the statistical estimand behind the reported result. This approach avoids overstating cross-trial comparisons and helps distinguish what clinical research has demonstrated from what remains uncertain.